Skip to main content
ZJAMP Group Co., Ltd. logo

ZJAMP Group Co., Ltd. — Investor Relations & Filings

Ticker · 002758 ISIN · CNE100002029 LEI · 3003009OKT32LB5C0T64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,563 across all filing types
Latest filing 2019-09-16 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002758

About ZJAMP Group Co., Ltd.

https://www.znjtgf.com

ZJAMP Group Co., Ltd. specializes in the comprehensive distribution and supply chain management of agricultural production materials. The company’s core operations encompass the procurement, storage, and sale of essential inputs, including chemical fertilizers such as urea, potash, and compound fertilizers, as well as pesticides, seeds, and agricultural machinery. Beyond product distribution, the organization provides integrated technical services, modern logistics solutions, and agricultural consultancy to enhance crop yields and farming efficiency. By leveraging an extensive network of distribution centers and service stations, the group facilitates the stable supply of high-quality agricultural resources. Its business model focuses on bridging the gap between manufacturers and end-users through efficient resource allocation and value-added services.

Recent filings

Filing Released Lang Actions
独立董事关于对评估机构的独立性、评估假设前提的合理性、评估方法与评估目的的相关性以及评估定价的公允性的独立意见
Regulatory Filings Classification · 90% confidence The document is an independent opinion from independent directors regarding the fairness and independence of an asset valuation related to a major asset restructuring transaction involving share purchase. It discusses the evaluation agency's independence, the reasonableness of assumptions, the relevance of evaluation methods, and the fairness of the pricing. The document references regulatory rules related to major asset restructuring and is focused on the fairness opinion rather than the full asset evaluation report or the transaction announcement itself. It is not a full annual or interim report, nor a call transcript or earnings release. It is a specialized opinion related to a major asset restructuring transaction, which fits best under the category of Regulatory Filings (RNS) as it does not contain full financial statements or detailed transaction documents but is a regulatory disclosure related to the transaction.
2019-09-16 Chinese
关于本次重大资产重组涉及各主要股东权益变动的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Zhejiang Huatong Pharmaceutical Co., Ltd. regarding a major asset restructuring involving changes in major shareholders' equity. It details the issuance of shares to purchase assets, changes in controlling shareholders and actual controllers, and the shareholding structure before and after the transaction. The document includes specific dates, shareholder percentages, and references to regulatory approvals and disclosures. It is not a full financial report but an announcement about a significant capital and ownership change related to a major asset reorganization. The document length is 2786 characters, which is relatively short and focused on the transaction and shareholder changes rather than comprehensive financial data or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2019-09-16 Chinese
关于本次发行股份购买资产暨关联交易事项摊薄即期回报情况及采取填补措施的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhejiang Huatong Pharmaceutical Co., Ltd. regarding the issuance of shares to purchase assets and related party transactions, specifically addressing the dilution of immediate returns and measures to compensate for it. It references regulatory guidelines from Chinese authorities (CSRC and State Council) about capital market health and investor protection. The document includes financial impact analysis before and after the transaction, commitments by directors and controlling shareholders, and measures to enhance shareholder returns. The document is relatively short (2838 characters) and structured as a formal announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it focuses on disclosure related to a capital transaction and associated governance and compliance measures. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2019-09-16 Chinese
董事会关于发行股份购买资产暨关联交易的一般风险提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the board of Zhejiang Huatong Pharmaceutical Co., Ltd. regarding a planned issuance of shares to purchase assets and related party transactions. It includes a risk warning about potential regulatory investigations and the risk of suspension or termination of the transaction. The document is short (775 characters) and serves as a risk disclosure and announcement of a transaction proposal rather than a detailed report or financial statement. It does not contain financial data or detailed analysis but is an update on capital raising and asset acquisition activities. Therefore, it fits best under Capital/Financing Update (CAP).
2019-09-16 Chinese
第三届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed by the board of directors of Zhejiang Huatong Pharmaceutical Co., Ltd. regarding a major asset restructuring involving the issuance of shares to purchase assets and related party transactions. It includes detailed descriptions of the transaction, pricing, payment methods, lock-up periods, performance commitments, legal compliance, and audit and asset appraisal reports. The document references compliance with Chinese securities laws and regulations related to major asset restructurings and non-public share issuance. It is a formal board meeting resolution announcement that requires shareholder approval. The content is focused on corporate governance decisions and transaction approvals rather than financial results, earnings, or audit opinions alone. It is not a full annual or interim report, nor a call transcript or earnings release. It is not a proxy solicitation or voting results announcement, but a board/management information disclosure about significant corporate actions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice.
2019-09-16 Chinese
发行股份购买资产暨关联交易报告书（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled "浙江华通医药股份有限公司 发行股份购买资产暨关联交易报告书（草案）摘要" which translates to "Zhejiang Huatong Pharmaceutical Co., Ltd. Issuance of Shares to Purchase Assets and Related Party Transaction Report (Draft) Summary." It includes extensive information about a major asset restructuring transaction, including transaction parties, asset valuations, financial data from 2018, issuance of shares as payment, lock-up periods for shares, and compliance with regulatory requirements. The document references the China Securities Regulatory Commission (中国证监会) and Shenzhen Stock Exchange (深交所), and discusses the transaction as a "重大资产重组" (major asset restructuring) and "重组上市" (restructuring listing). It contains substantive financial data, transaction details, and legal and procedural disclosures. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report publication, nor a full annual or interim report, nor a proxy or voting announcement. Therefore, the correct classification is CAP with high confidence.
2019-09-16 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.